Quick Takeaways
- Vivo Opportunity Fund Holdings, L.P. filed SCHEDULE 13G for SAB Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (SABS).
- Disclosed ownership: 10%.
- Date of event: 29 Sep 2025.
Vivo Opportunity Fund Holdings, L.P. - 29 Sep 2025 SCHEDULE 13G Report for SAB Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (SABS)
- Filing Manager
- Vivo Opportunity Fund Holdings, L.P.
- Reporting Manager
- Vivo Opportunity Fund Holdings, L.P.
- Symbol
- SABS
- Shares outstanding
- 259,569,570 shares
- Disclosed Ownership
- 25,931,000 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G
- Filing time
- 03 Oct 2025, 16:30:36 UTC
- Date of event
- 29 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Vivo Opportunity Fund Holdings, L.P. disclosed 10% ownership in SAB Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (SABS) on 29 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 03 Oct 2025, 16:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 10% | 25,931,000 | 25,931,000 | 0 | /s/ Kevin Dai | Kevin Dai/Managing Member of General Partner | |
| Vivo Opportunity, LLC | 10% | 25,931,000 | 25,931,000 | 0 | /s/ Kevin Dai | Kevin Dai/Managing Member | |
| Vivo Opportunity Cayman Fund, L.P. | 10% | 2,619,000 | 2,619,000 | 0 | /s/ Kevin Dai | Kevin Dai/Managing Member of General Partner | |
| Vivo Opportunity Cayman, LLC | 10% | 2,619,000 | 2,619,000 | 0 | /s/ Kevin Dai | Kevin Dai/Managing Member |